In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma Plc (VRNA), with a price target of $56. The company’s shares closed yesterday at $5.81, close to its 52-week low of $5.52.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -9.7% and a 37.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Verona Pharma Plc has an analyst consensus of Moderate Buy, with a price target consensus of $31.
See today’s analyst top recommended stocks >>
Based on Verona Pharma Plc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.05 million. In comparison, last year the company had a GAAP net loss of $8.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma’s product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
